Common genetic variants in PNPLA3 and TM6SF2 have been shown to increase the risk and severity of NAFLD, whereas single nucleotide polymorphisms (SNPs) in MTARC1 and HSD17B13 have protective effects (16–19). Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.